Last reviewed · How we verify
Hylorel (GUANADREL)
Hylorel (Guanadrel) is a small molecule drug developed by Pharmacia and Upjohn that targets the alpha-1A adrenergic receptor. It is classified as a guanadrel and was FDA approved in 1982 for the treatment of hypertensive disorders. As an off-patent medication, there are currently no generic manufacturers. Key safety considerations include its potential effects on blood pressure and heart rate. Hylorel is a vasodilator that works by blocking the alpha-1A adrenergic receptor, leading to decreased peripheral resistance and lowered blood pressure.
At a glance
| Generic name | GUANADREL |
|---|---|
| Sponsor | Pfizer |
| Drug class | guanadrel |
| Target | Alpha-1A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
- Hypertensive disorder
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |